GlassScriptPhysician profile
Raphaela Gassanov
NPI 1780388454
$6,364.27
in general payments reported to CMS, 2019-2025
18 companies · $3,694 in 2025
The $3,694 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $192 · 2024: $2,478 · 2025: $3,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,364.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,391.67 | 2024-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $880.14 | 2024-2025 | |
| Viiv Healthcare Company | $858.53 | 2024-2025 | Apretude |
| Novartis Pharmaceuticals Corporation | $346.00 | 2025 | |
| Glaxosmithkline, LLC. | $343.99 | 2023-2025 | Trelegy Ellipta, Nucala |
| Abbvie INC. | $322.01 | 2025 | |
| Genentech USA, INC. | $294.98 | 2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $257.14 | 2023-2025 | Dupixent |
| Incyte Corporation | $185.21 | 2025 | Opzelura, Opzelura |
| Harmony Biosciences LLC | $136.17 | 2023-2025 | Wakix |
| Kaleo, INC. | $90.40 | 2024 | Auvi-Q |
| Shield Therapeutics INC | $87.87 | 2024-2025 | |
| Ardelyx, INC. | $48.62 | 2025 | Ibsrela |
| Boston Scientific Corporation | $27.40 | 2023 | Wavewriter Alpha Prime 16 |
| Exact Sciences Corporation | $24.03 | 2025 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $23.97 | 2024 | |
| Lilly USA, LLC | $23.35 | 2025 | Zepbound, Mounjaro |
| Hologic Sales and Service, LLC | $22.79 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphaela Gassanov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.